Trial · NCT00512876
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
NCT00512876, Not applicable, Completed, Walter Reed Army Medical Center; results first posted 2013-07-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization. Trials, record NCT00512876. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00512876
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
- NCT number
- NCT00512876
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- Walter Reed Army Medical Center
- Conditions
- Corneal Neovascularization
- Interventions
- Bevacizumab (Avastin)
- First posted
- 2007-08-08
- Last updated
- 2013-07-22
- Results first posted
- 2013-07-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events (Ocular and Systemic) | 24 weeks | |
| Secondary | Size and Extent of Corneal Neovascularization | 24 weeks | computerized image analysis of the corneal photographs were used to measure the change in size and extent of corneal neovascularization from baseline. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Adverse Events (Ocular and Systemic) | 24 weeks | participants | NUMBER | |
| SECONDARY | Size and Extent of Corneal Neovascularization | 24 weeks | percentage change | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adverse Events (Ocular and Systemic) | Topical Avastin 1.0% | 0 | participants | ||
| Size and Extent of Corneal Neovascularization | Topical Avastin 1.0% | 27.9 | Standard Deviation 9.2 | percentage change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topical Avastin 1.0% | 24 | |
| Overall Study | COMPLETED | Topical Avastin 1.0% | 20 | |
| Overall Study | NOT COMPLETED | Topical Avastin 1.0% | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topical Avastin 1.0% | ||
| Total, other adverse events | Topical Avastin 1.0% | 0 | 24 |
| Total, serious adverse events | Topical Avastin 1.0% | 0 | 24 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00512876
GET https://conductscience.org/api/trials/v1/NCT00512876/registered